Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial

Author:

Tedeschi Alessandra1,Tam Constantine S2,Owen Roger G3,Buske Christian4,Leblond Véronique5,Dimopoulos Meletios6,Garcia-Sanz Ramón7ORCID,Castillo Jorge J8ORCID,Trotman Judith9,Treon Steven P8,Yang Keri10,Tang Boxiong10,Allewelt Heather10,Patel Sheel10,Chan Wai Y10,Cohen Aileen10,Chen Shengnan11,Barnes Gisoo10ORCID

Affiliation:

1. ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

2. Alfred Health & Monash University, Melbourne, Victoria, Australia

3. St. James University Hospital, Leeds, UK

4. Institute of Experimental Cancer Research, CCCU, University Hospital Ulm, Baden-Württemberg, Germany

5. Sorbonne University, Pitié Salpêtrière Hospital, Paris, France

6. Department of Clinical Therapeutics, National & Kapodistrian University of Athens, Athens, Greece

7. Hospital Universitario de Salamanca, CIBERONC, Universidad de Salamanca, IBSAL, Salamanca, Spain

8. Bing Center for Waldenström Macroglobiulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

9. Concord Repatriation General Hospital & University of Sydney, New South Wales, Australia

10. BeiGene USA, Inc., San Mateo, CA, USA

11. BeiGene (Shanghai) Co., Ltd, Shanghai,China

Funder

BeiGene

Publisher

Informa UK Limited

Reference17 articles.

1. Systematic literature review of quality‐of‐life questionnaires in Waldenström macroglobulinaemia—need for a disease‐specific tool

2. WhiMSICAL : A global Waldenström's Macroglobulinemia patient‐derived data registry capturing treatment and quality of life outcomes

3. Health‐related quality of life in Waldenstrom Macroglobulinemia and IgM‐related disorders: A single institution experience

4. Brukinsa (zanubrutinib) [package insert] [Internet]. BeiGene. 2021 [cited 2024 Mar 29]. Available from: www.brukinsa.com/prescribing-information.pdf

5. Waldenström macroglobulinemia/lymphoplasmacytic lymphoma v1.2023 [Internet];NCCN clinical practice guidelines in oncology;National Comprehensive Cancer Network.,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3